TY - JOUR AU - Péterfia, Csaba AU - Komlósi, Zsolt I. AU - Pós, Zoltán AU - Lupsa, Nikolett AU - Fekete, Nóra AU - Böröcz, Katalin AU - Dergez, Tímea AU - Leibinger, Evelin A. AU - Benedek, Noémi AU - Vojcek, Ágnes AU - Horváth, Bence AU - Vertike, Vita AU - Csanádi, Krisztina AU - Hauser, Péter AU - Tiszlavicz, Lilla Györgyi AU - Erdélyi, Dániel AU - Brückner, Edit AU - Szabó, Sándor AU - Beniczky, Nikolett Jusztina AU - Berki, Timea AU - Ottóffy, Gábor TI - Possible role of pre-vaccination T-lymphocyte subpopulations in the antibody response to COVID-19 vaccines in children undergoing chemotherapy JF - FRONTIERS IN IMMUNOLOGY J2 - FRONT IMMUNOL VL - 17 PY - 2026 SN - 1664-3224 DO - 10.3389/fimmu.2026.1728845 UR - https://m2.mtmt.hu/api/publication/36926625 ID - 36926625 LA - English DB - MTMT ER - TY - GEN AU - Hauser, Péter TI - EWING PY - 2025 UR - https://m2.mtmt.hu/api/publication/35774211 ID - 35774211 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Péterffy, Borbála AU - Krizsán, Szilvia AU - Egyed, Bálint AU - Bedics, Gábor AU - Benard-Slagter, Anne AU - Palit, Sander AU - Erdélyi, Dániel AU - Müller, Judit AU - Nagy, Tibor AU - Hegyi, Lajos AU - Bekő, Anna AU - Kenéz, Lili Anna AU - Jakab, Zsuzsanna AU - Péter, György AU - Zombori, Marianna AU - Csanádi, Krisztina AU - Ottóffy, Gábor AU - Csernus, Katalin AU - Vojcek, Ágnes AU - Tiszlavicz, Lilla Györgyi AU - Gábor, Krisztina AU - Kelemen, Ágnes AU - Hauser, Péter AU - Kállay, Krisztián Miklós AU - Kertész, Gabriella AU - Gaál, Zsuzsanna AU - Szegedi, István AU - Barna, Gábor AU - Márk, Ágnes AU - Haltrich, Irén AU - Hevessy Zsuzsanna, Dóra AU - Ujfalusi, Anikó AU - Kajtár, Béla AU - Timár, Botond AU - Kiss, Csongor AU - Kriván, Gergely AU - Matolcsy, András AU - Savola, Suvi AU - Kovács, Gábor AU - Bödör, Csaba AU - Alpár, Donát TI - Molecular profiling reveals novel gene fusions and genetic markers for refined patient stratification in pediatric acute lymphoblastic leukemia JF - MODERN PATHOLOGY J2 - MODERN PATHOL VL - 38 PY - 2025 IS - 6 PG - 14 SN - 0893-3952 DO - 10.1016/j.modpat.2025.100741 UR - https://m2.mtmt.hu/api/publication/35798493 ID - 35798493 N1 - * Megosztott szerzőség AB - Risk-adapted treatment protocols conferred remarkable improvement in the survival rates of pediatric acute lymphoblastic leukemia/lymphoma (ALL/LBL). Nevertheless, clinical management is still challenging in certain molecular subgroups and in the presence of alterations associated with an increased rate of relapse. In this study, disease-relevant genomic and transcriptomic profiles were established in a prospective, multicenter, real-world cohort involving 192 children diagnosed with ALL/LBL. Gene fusions were detected in 34.9% of B-ALL and 46.4% of T-ALL patients, with novel chimeric genes involving JAK2, KMT2A, PAX5, RUNX1 and NOTCH1, and with KMT2A-rearranged patients displaying the worst 3-year event-free survival (p=0.019). Non-synonymous mutations were uncovered in 74.9% of the analyzed patients, and a pairwise scrutiny of genetic lesions revealed recurrent clonal selection mechanisms commonly converging on the same pathway (e.g. Ras, JAK/STAT and Notch) in individual patients. Investigation of matched diagnostic and relapse samples unraveled complex subclonal variegation, and mutations affecting the NT5C2, TP53, CDKN2A, and PIK3R1 genes, emerging at the time of relapse. TP53 and CREBBP mutations, even as subclonal aberrations, were associated with shorter 3-year event-free survival among all patients with B-ALL (TP53 mutant vs wild-type: p=0.008, CREBBP mutant vs wild-type: p=0.010); and notably, B-ALL patients showing no measurable residual disease on day 33 could be further stratified based on TP53 mutational status (p<0.001). Our in-depth molecular characterization performed across all risk groups identified novel opportunities for molecularly targeted therapy in 55.9% of high-risk and in 31.6% of standard/intermediate-risk patients. LA - English DB - MTMT ER - TY - JOUR AU - Persson, K AU - Grønbæk, J AU - Tiberg, I AU - Fyrberg, Å AU - Castor, C AU - Andreozzi, B AU - Frič, R AU - Hauser, Péter AU - Kiudeliene, R AU - Mallucci, C AU - Mathiasen, R AU - Nyman, P AU - Pizer, B AU - Sehested, A AU - Boeg Thomsen, D TI - Postoperative word-finding difficulties in children with posterior fossa tumours. a crosslinguistic European cohort study. TS - a crosslinguistic European cohort study. JF - CHILDS NERVOUS SYSTEM J2 - CHILD NERV SYST VL - 41 PY - 2025 IS - 1 PG - 14 SN - 0256-7040 DO - 10.1007/s00381-025-06787-4 UR - https://m2.mtmt.hu/api/publication/36062788 ID - 36062788 AB - Posterior fossa tumour (PFT) surgery carries a risk of mutism or severely reduced speech. As for higher-cognitive language functions, word-finding difficulties have been reported, but no study has compared pre- and postoperative word-finding speeds to identify impairment caused by surgery. The current study investigated changes in word-finding ability associated with PFT surgery and examined factors affecting postoperative ability.We included 184 children aged 5:0-17:9 years undergoing PFT surgery and assessed word-finding ability before and after surgery using a speeded picture-naming test. We compared postoperative word-finding performance with both preoperative performance and age-specific norms and examined factors affecting word-finding ability.We found no significant difference between pre- and postoperative performance, reflecting that some children exhibited better word-finding ability after surgery, others poorer. After surgery, 95% of the children performed two standard deviations above (slower than) age-specific norms. Tumour location in the fourth ventricle negatively affected postoperative word-finding ability (B = -4.09, p < 0.05).For some children, PFT surgery leads to postoperative word-finding difficulties, emphasizing the importance of postoperative language assessments and interventions. Fourth-ventricle tumour location emerged as a risk factor for poorer postoperative word-finding ability, likely reflecting surgical damage to the dentato-thalamo-cortical pathway (DTCP). LA - English DB - MTMT ER - TY - JOUR AU - Laustsen, Aske Foldbjerg AU - Avula, Shivaram AU - Grønbæk, Jonathan AU - Pizer, Barry AU - Nyman, Per AU - Nilsson, Pelle AU - Frič, Radek AU - Hjort, Magnus Aasved AU - Beneš, Vladimír AU - Hauser, Péter AU - Pálmafy, Beatrix AU - Rutkauskiene, Giedre AU - Wilhelmy, Florian AU - Brandsma, Rick AU - Sehested, Astrid AU - Mathiasen, René AU - Juhler, Marianne TI - Tumour volume as a predictor of postoperative speech impairment in children undergoing resection of posterior fossa tumours. a prospective, multicentre study. TS - a prospective, multicentre study. JF - ACTA NEUROCHIRURGICA J2 - ACTA NEUROCHIR VL - 167 PY - 2025 IS - 1 PG - 9 SN - 0001-6268 DO - 10.1007/s00701-025-06459-x UR - https://m2.mtmt.hu/api/publication/36076974 ID - 36076974 N1 - Journal Article; Multicenter Study AB - Cerebellar Mutism Syndrome (CMS) is a neurological complication of posterior fossa (PF) tumour surgery in children, and postoperative speech impairment (POSI) is the cardinal symptom of CMS. The role of tumour volume on the risk of POSI remains unexplored. This study investigates the association between tumour volume and the risk of POSI.We included 360 patients from the European CMS study with available preoperative T1-weighted contrast-enhanced brain MRI. Speech status was assessed within two weeks postoperatively and categorised into three levels: habitual speech, severely reduced speech, and mutism. Tumour volumes were calculated using the BrainLab Elements SmartBrush™, a semi-automated segmentation tool. We used proportional odds models to estimate the odds ratio (OR) with adjustments for tumour location, pathology, and age. Based on the primary analysis, a risk stratification model for medulloblastoma patients was constructed, and the optimal volume cut-off was determined with Youden's Index.We found no effect of the overall tumour volume on the risk of POSI. This result did not change when adjusted for tumour location, pathology, and age. We found an association between tumour volume of medulloblastoma and the risk of POSI (unadjusted OR of 1.04 per increase in cm3 (95% CI 1.01;1.07, p = 0.01)), which did not change when adjusting for tumour location and age. The risk stratification cut-off for the tumour volume of medulloblastoma was calculated to be 16,5 cm3. Patients with medulloblastoma and preoperative tumour volumes below 16,5 cm3 had an absolute risk of 13% for POSI (low-risk group), whereas patients with preoperative tumour volumes above 16,5 cm3 had an absolute risk of 50% for POSI (high-risk group).Our data showed an association between preoperative tumour volume and the risk of POSI in children with medulloblastoma, while no association was found for the volume of other tumour types. We suggest a straightforward cut-off risk model for assessing the risk of POSI in children with medulloblastoma based on preoperative tumour volume. This approach can aid clinicians in informing patients and parents about the complications related to CMS following PF tumour surgery in children.ID NCT02300766 (October 2014). LA - English DB - MTMT ER - TY - JOUR AU - Sarup, R. AU - Laustsen, A.F. AU - Sørensen, M.K. AU - Mallucci, C. AU - Pizer, B. AU - Aquilina, K. AU - Molinari, E. AU - Hjort, M.A. AU - Frič, R. AU - Nyman, P. AU - Sabel, M. AU - Nilsson, P. AU - Matukevičius, A. AU - Hauser, Péter AU - Mudra, Katalin AU - Carai, A. AU - Zipfel, J. AU - Hoving, E. AU - van, Baarsen K. AU - IIIrd, V.B. AU - Peyrl, A. AU - Nysom, K. AU - Sehested, A.M. AU - Schmiegelow, K. AU - Juhler, M. AU - Grønbæk, J.K. AU - Mathiesen, R. TI - Glucocorticoid use in paediatric posterior fossa tumour surgery and the occurrence of postoperative speech impairment JF - CHILDS NERVOUS SYSTEM J2 - CHILD NERV SYST VL - 41 PY - 2025 IS - 1 PG - 11 SN - 0256-7040 DO - 10.1007/s00381-025-06850-0 UR - https://m2.mtmt.hu/api/publication/36263026 ID - 36263026 LA - English DB - MTMT ER - TY - JOUR AU - Laustsen, Aske Foldbjerg AU - Gronbaek, Jonathan Kjaer AU - Fric, Radek AU - Avula, Shivaram AU - Mallucci, Conor AU - Nilsson, Pelle AU - Nyman, Per AU - Hauser, Péter AU - Mudra, Katalin AU - Kiudeliene, Rosita AU - Rocka, Saulius AU - Hjort, Magnus Aasved AU - Brandsma, Rick AU - Hoving, Eelco AU - Carai, Andrea AU - Benes, Vladimir AU - Taborska, Jana AU - Dorfer, Christian AU - Jacobs, Sandra AU - Pavon-Mengual, Miriam AU - Skjoth-Rasmussen, Jane AU - Schmiegelow, Kjeld AU - Sehested, Astrid AU - Mathiasen, Rene AU - Juhler, Marianne TI - Postoperative speech impairment and cranial nerve deficits in children undergoing posterior fossa tumor surgery with intraoperative MRI - a prospective multinational study JF - ACTA NEUROCHIRURGICA J2 - ACTA NEUROCHIR VL - 167 PY - 2025 IS - 1 PG - 11 SN - 0001-6268 DO - 10.1007/s00701-025-06669-3 UR - https://m2.mtmt.hu/api/publication/36355531 ID - 36355531 AB - Background Postoperative speech impairment (POSI) and cranial nerve deficits (CND) are common complications of pediatric posterior fossa (PF) tumor surgery. Intraoperative MRI (ioMRI) has proven a useful tool in achieving gross total resection. The risk of POSI and CND with ioMRI remains unclear, making it the primary scope of this study. Additionally, we assessed whether POSI was associated with CND. Methods We prospectively included pediatric patients undergoing PF tumor surgery in 36 centers across 15 European countries. Neurological status and speech were assessed preoperatively and 1-4 weeks postoperatively. Surgical details, including tumor location and use of ioMRI, were recorded within 72 h of surgery. Postoperative CND were categorized as 0, 1, 2, or >= 3 nerves affected; POSI as habitual, reduced speech, or mutism. Proportional odds models estimated odds ratios (OR) for 1) POSI with stepwise adjustment for tumor location and age, and 2) CND with adjustment for preoperative CND and tumor location. Subgroup analyses assessed systematic differences, missing data, center-level effects, and histology adjustment. ResultsOf 790 primary PF tumor surgeries, 141 (18%) involved ioMRI. POSI occurred in 183/790 (23%) and postoperative CND in 213/790 (27%). POSI-risk with ioMRI showed non-significant unadjusted OR (95% CI) 0.83 (0.53;1.30); adjusted OR 0.76 (0.43;1.35). Fewer CNDs were observed with ioMRI (unadjusted OR 0.63 (0.40;1.00), adjusted OR 0.58 (0.33;0.94), p = 0.03). POSI-risk was associated with more CNDs (adjusted OR for 1 CND: 2.06 (1.15;3.68); 2 CND: 2.13 (1.02;4.42); >= 3 CND: 4.15 (1.98;8.70), p < 0.05). Conclusions ioMRI was not associated with increased risk of postoperative complications in this multicenter cohort. The reduction in CND among ioMRI cases may reflect derived effects on surgical decision-making, expertise, case-load and case-mix. Results should be interpreted with caution due to limited intraoperative data. The association between POSI-risk and cumulative CND may indicate extensive brainstem involvement. Our findings highlight the need to further explore how ioMRI-guided strategies affect functional outcomes in pediatric PF tumour surgery. LA - English DB - MTMT ER - TY - JOUR AU - Hernádfői, Márk Viktor AU - Szabados, Márton AU - Brückner, Edit AU - Varga, Ágnes AU - Hauser, Péter AU - Ottóffy, Gábor AU - Vojcek, Ágnes AU - Csanádi, Krisztina AU - Kertész, Gabriella AU - Jakab, Zsuzsanna AU - Agócs, Gergely AU - Garami, Miklós TI - Dinutuximab Beta for the Treatment of High-Risk Neuroblastoma : Data from the Hungarian Pediatric Oncology Network JF - JOURNAL OF CLINICAL MEDICINE J2 - J CLIN MED VL - 14 PY - 2025 IS - 18 PG - 15 SN - 2077-0383 DO - 10.3390/jcm14186641 UR - https://m2.mtmt.hu/api/publication/36366328 ID - 36366328 AB - Background/Objectives: The anti-GD2 monoclonal antibody dinutuximab beta has become standard of care maintenance therapy for high-risk neuroblastoma (HR-NB) in the first-line setting and is also approved in the relapsed/refractory setting. We present a retrospective review of 37 children with HR-NB included in the Hungarian Childhood Cancer Registry who received dinutuximab beta (first-line maintenance therapy, n = 31; relapsed/refractory, n = 6). Methods: All patients received dinutuximab beta continuously over the first 10 days of each 35-day cycle, with dosing based on body surface area/weight. Five cycles were planned, with further cycles administered at the treating physician's discretion. Results: At data cutoff, the overall disease control rate was 54.1% (20/37) (complete response, 51.4% (19/37); partial response, 0.0% (0/37), stable disease, 2.7% [1/37]); two patients (5.4%) had progressive disease, and 15 patients (40.5%) had died. The 5-year overall survival (OS) and event-free survival (EFS) rates in the overall population were 63.3% (95% confidence interval, 49.1-81.7) and 56.2% (95% confidence interval, 42.1-75.0), respectively. Grade 3 or 4 adverse events (including blood and lymphatic system disorders, hypoxia, hypotension, and capillary leak syndrome) were generally consistent with dinutuximab beta's known safety profile. Conclusions: Dinutuximab beta was an effective immunotherapy for patients with HR-NB in routine clinical practice, with a generally manageable side effect profile. LA - English DB - MTMT ER - TY - CHAP AU - Hauser, Péter AU - Garami, Miklós ED - Tulassay, Tivadar TI - A központi idegrendszer daganatai T2 - Klinikai gyermekgyógyászat PB - Medicina Könyvkiadó CY - Budapest SN - 9789632268873 PY - 2024 SP - 787 EP - 788 PG - 2 UR - https://m2.mtmt.hu/api/publication/34200801 ID - 34200801 LA - Hungarian DB - MTMT ER - TY - CHAP AU - Hauser, Péter AU - Garami, Miklós ED - Tulassay, Tivadar TI - Gliomák T2 - Klinikai gyermekgyógyászat PB - Medicina Könyvkiadó CY - Budapest SN - 9789632268873 PY - 2024 SP - 788 EP - 790 PG - 4 UR - https://m2.mtmt.hu/api/publication/34200803 ID - 34200803 LA - Hungarian DB - MTMT ER -